Clinical Trial Update: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on rogaratinib (BAY 1163877) for FGFR1-4-altered advanced sarcoma and SDH-deficient gastrointestinal stromal tumor (GIST), with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Soft Tissue Sarcoma

Drugs mentioned

• Rogaratinib (BAY 1163877) (rogaratinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING